Scholars Central

Conference abstractPublished 2 Nov 2015

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomized controlled trials

Authors: David R Owens, Louise Traylor, Wolfgang Landgraf

Swansea University, UK; Sanofi US, Inc, USA; Sanofi Deutschland, Germany

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Aim: Evaluate early (0Ã?¢Ã?Â?Ã?Â?12 weeks) and later (12Ã?¢Ã?Â?Ã?Â?24 weeks) treatment outcomes after addition of insulin glargine in subjects with type 2 diabetes not achieving glycaemic control with oral anti-diabetes drugs (OADs). Methods: Selected data were pooled from 15 randomized, controlled treat-to-target (fasting plasma glucose <100 mg/dL [<5.6 mmol/L]) trials adding insulin glargine to metformin, a sulphonyl urea, or both. Glycaemic and hypoglycaemia parameters, insulin dose and body weight at weeks 12 and 24 were assessed using individualized subject-level data. Results: Data from 2837 subjects were analysed. HbA1c decreased from 8.8% (73 mmol/mol) at baseline by 1.4% (15mmol/mol) at week 12 and a further 0.2% (2mmol/mol) at Week 24 in the pooled population. Similar reductions were observed across the different treatment groups. HbA1c <7.0% (<53 mmol/mol) was reached by 34.8% of participants at week 12 and an additional 24.3% by week 24. Hypoglycaemia incidence and rates were similar during the early and continued treatment periods across all treatment combinations, but were markedly lower for insulin glargine plus metformin versus the other 2 regimens (P<0.001 for incidence and events rates of overall hypoglycaemia with blood glucose <70 mg/dL during weeks 0Ã?¢Ã?Â?Ã?Â?12 and P<0.001 for events rates of overall hypoglycaemia with blood glucose <70 mg/dL during weeks 12Ã?¢Ã?Â?Ã?Â?24). Conclusions: Early and sustained glycaemic benefits with a low-risk of hypoglycaemia are observed after initiation of insulin glargine in a pooled type 2 diabetes cohort previously uncontrolled on OADs.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Endocrinology & Metabolic Syndrome.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalEndocrinology & Metabolic Syndrome
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “David R Owens”
  • BylineArticles whose byline prints “Louise Traylor”
  • BylineArticles whose byline prints “Wolfgang Landgraf”